Literature DB >> 9641673

HIV. Envelope's letters boxed into shape.

J P Moore, J Binley.   

Abstract

Mesh：

Substances：

Year:  1998        PMID： 9641673     DOI： 10.1038/31359

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  18 in total

1.  Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits.

Authors:  R W Sanders; L Schiffner; A Master; F Kajumo; Y Guo; T Dragic; J P Moore; J M Binley
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

2.  Palmitoylation of the HIV-1 envelope glycoprotein is critical for viral infectivity.

Authors:  I Rousso; M B Mixon; B K Chen; P S Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

3.  Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques.

Authors:  I Ourmanov; M Bilska; V M Hirsch; D C Montefiori
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

4.  A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure.

Authors:  J M Binley; R W Sanders; B Clas; N Schuelke; A Master; Y Guo; F Kajumo; D J Anselma; P J Maddon; W C Olson; J P Moore
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

5.  Induction of humoral immune responses following vaccination with envelope-containing, formaldehyde-treated, thermally inactivated human immunodeficiency virus type 1.

Authors:  B Poon; J T Safrit; H McClure; C Kitchen; J F Hsu; V Gudeman; C Petropoulos; T Wrin; I S Y Chen; K Grovit-Ferbas
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

6.  Variants of human immunodeficiency virus type 1 that efficiently use CCR5 lacking the tyrosine-sulfated amino terminus have adaptive mutations in gp120, including loss of a functional N-glycan.

Authors:  Emily J Platt; Danielle M Shea; Patrick P Rose; David Kabat
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

7.  Shared usage of the chemokine receptor CXCR4 by primary and laboratory-adapted strains of feline immunodeficiency virus.

Authors:  J Richardson; G Pancino; R Merat; T Leste-Lasserre; A Moraillon; J Schneider-Mergener; M Alizon; P Sonigo; N Heveker
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

8.  CXCR4 is down-regulated in cells infected with the CD4-independent X4 human immunodeficiency virus type 1 isolate m7NDK.

Authors:  S T Valente; C Chanel; J Dumonceaux; R Olivier; S Marullo; P Briand; U Hazan
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

9.  Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.

Authors:  Rogier W Sanders; Mika Vesanen; Norbert Schuelke; Aditi Master; Linnea Schiffner; Roopa Kalyanaraman; Maciej Paluch; Ben Berkhout; Paul J Maddon; William C Olson; Min Lu; John P Moore
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

10.  The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.

Authors:  Rogier W Sanders; Miro Venturi; Linnea Schiffner; Roopa Kalyanaraman; Hermann Katinger; Kenneth O Lloyd; Peter D Kwong; John P Moore
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.